IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease (MRD) monitoring (CancerDetect™), and multi-cancer early detection (CancerFind™) using liquid biopsy-based NGS technology. | IMBdx is a liquid biopsy-focused precision oncology company that develops minimally invasive, comprehensive genomic profiling (CGP) assays. IMBdx Inc.’s AlphaLiquid® platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid®100) to recurrence and minimal residual disease (MRD) monitoring (CancerDetect™), AND multi-cancer early detection (CancerFind™). Our proprietary technology detects and analyzes trace amounts of tumor-derived DNA in body fluids using AI-driven bioinformatic algorithms. IMBdx is the dominant liquid biopsy diagnostics provider in South Korea and a growing liquid biopsy company globally. We also offer customized solutions for biopharma companies to assist in biomarker validation and companion diagnostics development. | < About IMBdx > IMBdx (In My Blood diagnostics) is a precision oncology company specializing in liquid biopsy technologies. We empower physicians and patients worldwide by providing advanced, non-invasive solutions for cancer detection, monitoring, and treatment guidance. Using a single blood draw, we analyze a broad spectrum of tumor-derived genetic alterations to offer actionable insights at a reasonable cost. Our in-house laboratory and proprietary analytical platforms are optimized for ultra-sensitive mutation detection. By integrating clinical big data with artificial intelligence, we support physicians in predicting treatment response and patient outcomes. < What is Liquid Biopsy? > Liquid biopsy is a minimally invasive method that detects circulating tumor DNA (ctDNA) in body fluids such as blood, cerebrospinal fluid, or pleural effusion. It offers a safer and simpler alternative to traditional tissue biopsy, enabling real-time monitoring of disease progression, therapy response, and early recurrence. < Our Core Solutions > 1. AlphaLiquid®100 Ultrasensitive ctDNA Liquid Biopsy Platform for Comprehensive Genomic Profiling AlphaLiquid100 provides comprehensive genomic profiling for patients with advanced solid tumors. It assesses alterations across 118 cancer-related genes, including 15 HRR genes and 10 gene fusions, to support personalized treatment planning, targeted therapy selection, and response monitoring. 2. CancerDetect™ Tumor-informed, Hybrid Capture-based ctDNA Assay for MRD Detection CancerDetect is an NGS-based, patient-customized assay designed for the detection of minimal residual disease (MRD) and recurrence surveillance in stage I–III solid tumors. It utilizes up to 500 tumor-informed and therapeutic targets, offering highly sensitive detection with a lead time advantage over radiological imaging. 3. CancerFind™ Accurate Multi-Cancer Early Detection with a Single Blood Test CancerFind enables early detection of eight major cancers—colon, stomach, liver, pancreatic, lung, breast, ovarian, and prostate—with one blood sample. By analyzing ctDNA with advanced technology, it not only detects cancer presence but also identifies the most likely tissue of origin, supporting early intervention and informed clinical decisions.
Huna
Supercharging routine blood exams with AI, Huna turns massive data into accessible cancer care. By partnering with global leaders and leveraging one of the world’s largest oncology datasets, we deliver scalable solutions for early detection and risk stratification. Our platform supports the full cancer journey—from triage to diagnosis and beyond—transforming standard lab data into powerful clinical insights. Huna makes cutting-edge innovation usable by real-world healthcare systems tackling one of the world’s biggest health challenges.
HoHo Biotech Co., LTD
HOHO Biotech is a Taiwan-based biotech company specializing in molecular hydrogen therapy as a clinically proven adjuvant for managing Autoimmune diseases, chronic Inflammation, and Cancer. Its flagship products include hydrogen capsules and H₂/O₂ inhalation devices, used in hospitals, clinics, and pharmacies. Backed by clinical trials and publications, HOHO Biotech offers a natural antioxidant and anti-inflammatory capsule that enhances drug efficacy and reduces side effects. Partnering with major medical centers, HOHO Biotech leads the field in hydrogen medicine, aiming for global expansion through research, regulatory approval, and partnerships. Search “HOHO Biotech hydrogen therapy” or visit www.hoholab.com.tw to learn more. HOHO Biotech LinkedIn: www.linkedin.com/company/hoho-biotech Benson LinkedIn: https://www.linkedin.com/in/kuang-yih-wang-ab14b621/ https://www.hohobio.com Website Taiwan: https://www.hoholab.com.tw/ Phone: +886920757313 Email: Benson@hohobio.com Industry Hospitals and Health Care Company size 2-10 employees 2 associated members LinkedIn members who’ve listed HOHO Biotech as their current workplace on their profile. Founded 1976 Specialties molecular hydrogen therapy, hydrogen capsules, anti-inflammatory capsule, autoimmune disease adjuvant, natural antioxidant supplement, hydrogen medicine Taiwan, H₂/O₂ inhalation device, clinical trial hydrogen therapy, reduce drug side effects, and HOHO Biotech Taiwan HoHo Biotech was founded in 2017. The company focuses on Autoimmune Disease, Hydrogen-Based Molecular Medicine, and gut microenvironment research. In 2018, it developed a “Hydrogen Capsule”, a proprietary natural coral calcium material. In 2020, it received TFDA approval, becoming a “Prescription use in Regional Hospital”, based on clinical trial data. In 2022, it became a “Prescription Use in Medical Center”. In 2024, Launched H2 Capsule in “Pharmacy Chains”, more than 200 shops. In 2024, HoHo introduced an AI molecular simulation system and built the Molecular Intelligence Engine, combining functional material science with computational modeling. In 2025, published more than 18+ Medical Papers as evidence of the “Hydrogen Capsule” as a perfect “Adjuvant” in the Autoimmune area. Launched HydroChat, an AI assistant for personalized applications. This development led to the company’s core strategy, Gut Engineering, which uses molecular signals to regulate the intestinal environment.
Gevers Belgium
Gevers is a leading European firm specializing in intellectual property (IP) services, with over 125 years of experience in empowering innovation. Headquartered in Belgium and France, Gevers provides expert support in patents, trademarks, designs, copyrights, and tailor-made IP strategies, helping businesses protect, manage, and maximize the value of their innovations. Gevers partners with visionary entrepreneurs, pioneering companies, and research institutions to secure their competitive edge in a fast-evolving world. Driven by its mission “Empowering Innovation,” Gevers acts as a guardian of progress — combining deep legal expertise with a proactive, down-to-earth, and entrepreneurial spirit. From initial IP filings to complex enforcement cases and strategic advisory, Gevers is a trusted ally throughout the innovation lifecycle.
Genomics
Genomics is a precision medicine company accelerating target discovery and clinical development through large-scale genomic insights powered by AI/ML-driven analysis. We were formed in 2014 by four ground-breaking statistical and human geneticists at the University of Oxford. Today, we are collaborating with some of the world’s leading innovators in drug development, enabling them to leverage genomics to de-risk decision making, identify and validate targets, improve trial success rates, and reduce trial time-to-completion. Our cutting-edge solutions support the advancement of groundbreaking therapies, enabling our partners to accelerate the discovery and commercialisation of next-generation treatments. | Genomics is a science-led transatlantic TechBio combining large-scale genetic and health data with proprietary analytics to accelerate drug discovery and advance predictive, preventative healthcare. Spun out of the University of Oxford in 2014 by the world’s top statistical and human geneticists, the company is built on a decade of world-class science and R&D. Its mission is to help people lead longer, healthier lives.
Fondazione Ri.MED
The Ri.MED Foundation develops innovative biotechnology and biomedical research aimed at timely transferring scientific discoveries in clinical practice. Ri.MED was established as an international partnership between Italian Government, Italian National Research Council (CNR), Region of Sicily, University of Pittsburgh, and UPMC. In 2017, Ri.MED entered the governance of the transplant-specialized hospital ISMETT, to create an integrated translational research and highly specialized care cluster, with the goal to rapidly transfer scientific results “from bench to bedside”. The Foundation is engaged in training highly qualified staff, disseminating scientific knowledge, and establishing and managing research centers and laboratories. Consistently with its mission, the Ri.MED Foundation has achieved important results, training several biotechnology professionals, publishing hundreds of scientific articles, generating intellectual property covered with filed patents (31 today), and promoting local scientific and public engagement events. Ri.MED manages laboratories in Sicily and, at the same time, is designing the Biomedical Research and Biotechnology Center (“BRBC”) that it is actually under construction near Palermo. The result of this strategy will foster innovative solutions for patients, and an increased ability to attract new funds. Ri.MED research stems from medical need to develop innovative solutions, and focuses on four main therapeutic areas: cancer, with special focus on immunotherapy; organ failure, including organ transplantation and regenerative medicine; infectious diseases; and aging-associated diseases, with a focus on neurodegeneration. Ri.MED’s scientific projects are based on three main areas of interest: regenerative medicine and immunotherapy, aimed at developing advanced therapy medicinal products (ATMP); new drug discovery research and development; and tissue engineering and biomedical bioengineering, focused on developing biomaterials, engineered tissues, and medical devices. The activities range from identifying new biologically active molecules to developing cellular products for tissue repair and/or regeneration, and organotypic cultures for regenerative purposes and as models for pharmacology screening, and all the way to simulation of physiological systems and preclinical validation of new generation implantable organs and devices. Ri.MED has a diversified and balanced project portfolio led by a multidisciplinary team with clear product development goals and a “bench-to-bedside” approach. The translational research engine of Ri.MED Foundation envisages the development of 10 skills and technology platforms supporting scientific projects: Biophysics and Structural Biology, High Throughput Screening, Bioinformatics and Molecular Informatics, Advanced Data Analysis, Biomedical Imaging and Radiomics, Proteomics, Cell factory for the production of ATMP, Medicinal Chemistry, Bioengineering and Tissue Engineering. Scientific dissemination and sharing research outcomes are part of the Foundation’s mission. This involves developing a wide network of collaborations and scientific agreements with institutions in strategic areas of interest: 16 new agreements in 2022. Training highly qualified personnel is not only part of Ri.MED’s mission, but a task the Foundation carries out with particular enthusiasm, understanding that offering high-level training can contribute to enriching the future of young people, and the competitiveness and development of Sicily. | The Foundation, based in Palermo, promotes, supports and leads biomedical and biotechnological research projects, with emphasis on the translation of innovative results into clinical practice. Ri.MED is currently focused on the creation of the Biomedical Research and Biotechnology Centre, which will be a reference point for researchers from all over the world. At the same time, the Foundation trains the researchers who will provide the human capital of the Research Centre. In preclinical and clinical research, strategic are the partnerships with the University of Pittsburgh, UPMC and IRCCS-ISMETT, which have yielded proprietary intellectual property resulting in several joint patent applications. The generation of intellectual property represents a fundamental intangible asset in the valorization of the Fondazione Ri.MED, with the perspective of developing an innovative model of sustainable research.
Flyps
Flyps is a high-tech software company specializing in deep tech, AI, and full-stack software development. We work globally, collaborating with partners across different time zones. Our team comprises senior engineers, many with Ph.D.s in computer science, data science, and IT. We excel in AI-powered solutions, including LLM applications, Computer Vision, Machine Learning, and Robotics, applied across high-tech, med-tech, bio-tech, agri-tech, and deep science industries. Our projects range from wildfire prevention and industrial automation to medical AI and predictive maintenance. We offer flexible cooperation models: full product development, R&D support, or team augmentation.
etherna
We are an RNA technology company, with over 30 years’ experience, offering professional partnerships to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage, and late stage projects using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners. | Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry to enable delivery of cost-effective, differentiated and efficacious RNA therapeutics.
Enzymaster Deutschland GmbH
Enzymaster is a one stop solution provider for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With our proprietary BioEngine® platform and long-term experience, we offer R&D services with establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical and other industries. Our portfolio includes: • Enzyme panel screening • Smart engineering of enzymes • Process development • Enzyme preparation by fermentation • Biocatalytic manufacturing • Enzyme Kits BioEngine® is our enzyme directed evolution platform, spearheaded by the integration of bioinformatics database guided design, computer protein modelling and simulations, as well as high throughput systems, thus highly efficient and reliable. The application of bioinformatics-assisted design and analysis of protein mutations leads to major time savings and higher success rates; whereas the automated and controlled laboratory procedures deliver higher accuracy and consistency of experimental results. | Enzymaster is a one stop solution provider for the development and commercialization of innovative and sustainable enzyme catalysis technologies. With our proprietary BioEngine® platform and long-term experience, we offer R&D services with establishment of complete technology transfer packages and manufacturing collaborations to fine chemical, pharmaceutical and other industries. Our portfolio includes: • Enzyme panel screening • Smart engineering of enzymes • Process development • Enzyme preparation by fermentation • Biocatalytic manufacturing • Customized and off-the-shelf enzyme kits BioEngine® is our enzyme directed evolution platform, spearheaded by the integration of bioinformatics database guided design, as well as computer protein modelling and simulations, thus highly efficient and reliable. The application of bioinformatics-assisted design and analysis of protein mutations leads to major time savings and higher success rates; whereas the automated and controlled laboratory procedures deliver higher accuracy and consistency of experimental results. To better serve our global customers, we have established a new independent R&D center in Germany. This facility provides contract research (CRO) services and supports smaller-scale production campaigns, offering a fast and flexible solution for enzyme and process development. At the same time, we continue to leverage cost-effective and rapid scale-up solutions in Asia for enzyme manufacturing and chemical production, ensuring efficiency at every stage of the process. Enzymaster strives to contribute to a greener environment and improve manufacturing processes by helping organisations leverage the benefits of biocatalysts, decreasing dependence on toxic and often inefficient, purely chemical syntheses. Flexible fee-for-service models moving in lockstep with R&D programmes, high success rates, commitment to confidentiality, and the avoidance of one-size-fits-all IP policies allow Enzymaster to advance biocatalysis innovation rather than impede it, ultimately fuelling the future of manufacturing.
ENCell Co., Ltd.
We are simultaneously conducting cell and gene therapy (CGT) CDMO business and cell therapy development business. Since its establishment as a spin-off from Samsung Medical Center in 2018, our CDMO business has accumulated differentiated technological capabilities based on diverse experiences in producing advanced biopharmaceuticals such as stem cells, CAR-T, AAV, and exosomes. We have executed 17 companies and 33 projects to date. Furthermore, In-Korea, our company holds the record for the most IND approvals among CGT CDMOs, establishing us as the leading company in this field domestically. We have filed a total of 23 patents related to our CDMO business, including markers for detecting stem cell proliferation and high-efficiency proliferation methods using them, expansion culture methods for cord blood-derived natural killer cells, artificial intelligence-based real-time cell image analysis methods, and their applications. Among these, four patents have been registered, and one paper has been published. | ENCell Co., Ltd. was founded in 2018 by Jongwook Chang, a professor at Samsung Medical Center and Sungkyunkwan University, who also serves as a professor. We are committed to offering end-to-end cell and gene therapy CDMO services of advanced biopharmaceuticals such as cell and gene therapies. Since the establishment of the company, starting with a consignment production contract for Hanmi’s glioblastoma treatment, we have carried out 33 projects to date, including consignment production of clinical trial drugs for 17 customers. including 10 clinical trial plan approvals for our clients. In December 2020, it was designated as a CCPC (Central cell processing center) to supply raw cells for CAR-T products for clinical trials of Janssen’s CAR-T products, and in April 2022, it was designated as a CCPC for Novartis’ CAR-T product Kymriah and is supplying raw cells. To date, the cumulative number of patients is more than 110. ENCell’s headquarters is located in Songpa-gu, Seoul, and the research center and GMP 1st factory are located within Samsung Medical Center. In 2021, GMP’s second factory, measuring approximately 1,000 pyeong, will be completed in Hanam City and is producing cell and gene therapy products, gene therapy products (AAV, etc.), exosomes, etc., including CAR-T products for clinical trials. In January 2022, the third GMP plant, a facility dedicated to the production of viral vectors, has been completed and is currently carrying out consignment production of AAV product for clinical trials. The exosome therapy consignment produced at GMP’s second plant in Hanam received approval for phase 1 clinical trials in the U.S., and CAR-T cell therapy and NK cell therapy received approval for domestic phase 1/2 clinical trials, so clinical products are also being supplied. In addition, we are accelerating orders for the production of various clinical grade viruses (Lentivirus, AdV, etc.), including AAV. In addition, ENCell completed the phase 1 clinical trial of a next-generation stem cell treatment under development for rare muscle diseases Charcot-Marie-Tooth disease and Duchenne muscular dystrophy as indications in 2022, along with CDMO business. In addition, the company is expanding its own pipeline with anti-cancer immune cell therapy products. Based on its solid research and development capabilities, ENCell has global-level CDMO capabilities. Currently, as the only CDMO company in Korea that can produce cell and gene therapy products simultaneously, it is leading Korea’s cell and gene therapy consignment production market and is continuing to grow to establish itself as a competitive global bio company.